Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 4/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | CHIT1 | Q13231 | 7/20 | 0.39 |
| ▸ | CHIA | Q9BZP6 | 7/20 | 0.39 |
| ▸ | CHI3L1 | P36222 | 5/20 | 0.39 |
| ▸ | CHI3L2 | Q15782 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22903610 | 1.00 | FPR2 (0.43) | FPR2KCNH2TP53STSCHIT1 | |
| SCHEMBL26439568 | 0.88 | KCNH2 (0.54) | FPR2KCNH2TP53CHIT1CHIA | |
| SCHEMBL26439359 | 0.86 | CHIT1 (0.51) | FPR2KCNH2TP53STSCHIT1 | |
| SCHEMBL22903589 | 0.83 | NR1H2 (0.37) | FPR2 | |
| SCHEMBL22903580 | 0.83 | NR1H2 (0.37) | FPR2 | |
| SCHEMBL18577482 | 0.83 | CHIT1 (0.57) | KCNH2STSCHIT1CHIACHI3L1 | |
| SCHEMBL18589408 | 0.83 | CHIT1 (0.57) | KCNH2STSCHIT1CHIACHI3L1 | |
| SCHEMBL18609869 | 0.83 | CHIT1 (0.57) | KCNH2STSCHIT1CHIACHI3L1 | |
| SCHEMBL18607914 | 0.83 | CHIT1 (0.57) | KCNH2STSCHIT1CHIACHI3L1 | |
| SCHEMBL18577086 | 0.81 | CHIT1 (0.60) | KCNH2STSCHIT1CHIACHI3L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11638707-B2 | Substituted amino triazoles useful as chitinase inhibitors | MOLECURE S.A. (PL) | 2023-05-02 | — | — | US | disclosed |
| EP-3999500-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS CHITINASE INHIBITORS | OncoArendi Therapeutics S.A. (PL) | 2022-05-25 | — | — | EP | disclosed |
| CN-114174280-A | Substituted aminotriazoles useful as chitinase inhibitors | 昂科艾伦迪治疗法公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2021009209-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS CHITINASE INHIBITORS | Oncoarendi Therapeutics S.A. (PL) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638707-B2 | Substituted amino triazoles useful as chitinase inhibitors | CHIT1, CHIA, CHI3L1 | FPR2 1416/4885KCNH2 3849/4885TP53 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.